Affiliation:
1. National Medical Research Center for Hematology
Abstract
Introduction. Patients with hematological malignancies are one of the most vulnerable groups to infectious diseases. Immune system dysfunction caused by the disease and/or its therapy negatively affects infection disease duration and severity, leads to an increased risk of death, and reduces the efficacy of vaccination. However, the precise compensatory mechanisms that allow patients with deficient cellular or humoral responses to fight viral infections have not been sufficiently studied.Aim: To systematize the knowledge of immune response formation in patients with hematological malignancies with humoral or cellular dysfunction.Main findings. In this review the features of the T-cell immune response in patients with hematological malignancies is explored, followed by a discussion on how the diversity of the T-cell receptor repertoire may be important in effective virus elimination and protection against SARS-CoV-2 virus infection.
Publisher
National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation